An observational study in Amyloidosis, Amyloidosis Cardiac and ATTR Amyloidosis Wild Type, sponsored by Paolo Milani. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Paolo Milani · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Amyloidosis with a site in Italy — 14 open to participants now, 17 under way, 7 of them phase 3. Amyloidosis · Italy.
Among the 52 studies in Amyloidosis with a site in Italy, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2024, is one of 14 observational ones, reaches primary completion later than 4 of the 16 other live ones, and was the 45th registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →14 of the 52 studies in Amyloidosis with a site in Italy are open now. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in Italy, United States, Argentina and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in Italy, United States, Argentina and 33 more countries
Ages 18–85
Eidos Therapeutics, a BridgeBio company · Sites in Italy, United States, Argentina and 21 more countries
Ages 18–75
AbbVie · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
Intellia Therapeutics · Sites in Italy, United States, Argentina and 23 more countries
Ages 18–90
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 25
First in 2001; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 190 across 83 observational studies indexed under Amyloidosis.
Median enrollment 160 across the 38 interventional studies, 365 across the 14 observational. Of the 33 that completed or were terminated, 17 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 52 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Paolo Milani as lead sponsor.
Paolo Milani has 1 study filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Amyloidosis with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05444920Fondazione IRCCS Policlinico San Matteo di PaviaThe Italian Transthyretin Amyloidosis Web-Network | 2026-12-31 |
| NCT06251778Paolo MilaniNatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis | 2027-01-26 |
| NCT04839003Fondazione IRCCS Policlinico San Matteo di PaviaA Registry of AL Amyloidosis (ReAL) | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 52 studies in Amyloidosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
All ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue tafamidis treatment, according to Italian Medicines Agency regulations. C onsidering the significant risk of developing heart rhythm disturbances due to cardiac amyloidosis, especially in transthyretin form (ATTRwt), in routine clinical practice a stricter heart rhythm monitoring is recommended in ATTRwt patients. Moreover, particular attention is usually paid for those who present atrio-ventricular and/or intraventricular block at the baseline electrocardiogram. Data about rhythm disturbances and diuretic dose need will be collected during the planned physical examination every six months and the Holter ECG monitoring requested by the physician at the end of every planned clinical evaluation.
All patients with a diagnosis of ATTRwt disease and eligible for tafamidis treatment according to the national drug regulatory agency criteria and no prior history of atrial trachy-arrhythmia and/or bradyarrhythmias in their past medical history will undergo screening procedure to be enrolled in the present study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cumulative incidence of atrial tachy-arrhythmia and brady-arrhythmias requiring pacemaker and/or defibrillator
All ATTRwt patients eligible for tafamidis with no prior history of atrial tachy-arrhythmia or brady-arrhythmias will be prospectively enrolled. The events (arrythmias incidence) will be collected by the usually rhythm monitoring that physician will recommend at the end of clinical evaluation according to clinical practice
Time frame: 18 months
patient diuretic dose need (i.e. Furosemide), reported as mg/Kg/die
Time frame: 18 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.
Of 52 observational studies under Amyloidosis, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 183. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.